1H-Inden-1-ol, 2,3-dihydro-4-(1-methylethyl)- | 535969-38-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 1H-Inden-1-ol, 2,3-dihydro-4-(1-methylethyl)-
• 英文别名: 4-propan-2-yl-2,3-dihydro-1H-inden-1-ol
• CAS: 535969-38-1
• 化学式: C₁₂H₁₆O
• 分子量: 176.25
• InChiKey: SOQDKXBCMBVTKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS
  申请人：Old David W.

  公开号：US20090270385A1

  公开（公告）日：2009-10-29

  Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein G, B, Y, and A are as described. Methods, compositions, and medicaments related thereto are also disclosed.

  本申请揭示了包含或其药用可接受的盐或其前药的化合物，其中G、B、Y和A如所述。还公开了与之相关的方法、组合物和药物。
• THERAPEUTIC COMPOUNDS
  申请人：Old David W.

  公开号：US20090270396A1

  公开（公告）日：2009-10-29

  Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein J 1 , J 2 , U 1 , B, Y, and A are as described. Methods, compositions, and medicaments related thereto are also disclosed.

  揭示了包含J1、J2、U1、B、Y和A的化合物，或其药用盐或前药。还公开了相关的方法、组合物和药物。
• Six membered heteroaromatic inhibitors targeting resistant kinase mutations
  申请人：Noronha Glenn

  公开号：US20070149508A1

  公开（公告）日：2007-06-28

  A compound is provided, having the general structure (A): wherein A is an (un)substituted aryl or (un)substituted heteroaryl moiety, G is N, CH, or CR, R is an unsubstituted or substituted lower alkyl, Y is a hydrophobic linking moiety, and L is a substitutent as defined. The compound (A) can be used for treatment of various angiogenic and hematological-associated disorders, such as myeloproliferative disorder in patients who do not respond to kinase-inhibition therapy that comprises administering approved medications.

  提供了一种化合物，其一般结构为(A)：其中A是(未)取代芳基或(未)取代杂环芳基基团，G是N、CH或CR，R是未取代或取代的较低烷基，Y是疏水连接基团，L是定义的取代基。化合物(A)可用于治疗各种与血管生成和血液学有关的疾病，例如在不对包括给予批准药物的激酶抑制治疗做出反应的患者中的骨髓增生性疾病。
• Thiazole inhibitors targeting resistant kinase mutations
  申请人：Noronha Glenn

  公开号：US20070161645A1

  公开（公告）日：2007-07-12

  A compound is provided, having the general structure (A): wherein A is an aryl or heteroaryl group, Y is a hydrophbic linking moiety, and L is a substitutent. The compound (A) can be used for treatment of various angiogenic-associated or hematologic disorders, such as myeloproliferative disorders in patients who do not respond to kinase-inhibition therapy that comprises administering currently used medications.

  提供了一种化合物，具有一般结构（A）：其中A是芳基或杂环芳基基团，Y是疏水连接基团，L是取代基。化合物（A）可用于治疗各种血管生成相关或血液学疾病，例如对于不对目前使用的药物进行激酶抑制治疗反应的患者的骨髓增生性疾病。
• US7429669B2
  申请人：——

  公开号：US7429669B2

  公开（公告）日：2008-09-30